正大天晴罗伐昔替尼刚获批即授权超15亿美元!石药、荣昌BD再现新苗头

医药经济报
Mar 04

根据协议条款,中国生物制药授予赛诺菲在全球范围内开发、生产及商业化罗伐昔替尼的独家许可。中国生物制药有权获得1.35亿美元的首付款,以及最高13.95亿美元的潜在开发、监管及销售里程碑付款,还将获得基于罗伐昔替尼年度净销售额的最高双位数阶梯式特许权使用费。值得注意的是,就在协议达成前数日,即2月28日,罗伐昔替尼刚刚获得国家药监局批准上市,用于中危-2或高危的原发性骨髓纤维化(PMF)、真性红细胞...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10